- The INFORM survey showed a 46% reduction in constant food thoughts after starting Wegovy®.
- 64% of respondents reported improved mental health on Wegovy®.
- 80% of participants developed healthier habits with Wegovy®.
- The STEP UP trial results were published in Lancet Diabetes Endocrinology on 14 September 2025.
Survey Findings
The INFORM survey, presented at the European Association for the Study of Diabetes 2025, revealed that individuals taking Wegovy® experienced a significant reduction in food noise, defined as unwanted and intrusive thoughts about food. The number of people reporting constant food thoughts decreased by 46% after starting the treatment.
Mental Health and Lifestyle Improvements
In addition to reducing food noise, 64% of respondents reported improved mental health while on Wegovy®. The survey also indicated that 80% of participants developed healthier habits, contributing to an overall healthier lifestyle.
Clinical Trials and Publications
Novo Nordisk continues to explore the impact of obesity on daily life, with upcoming presentations at EASD focusing on eating behavior and control with semaglutide from the STEP UP clinical trial. The full results of the STEP UP and STEP UP T2D clinical trials were published in Lancet Diabetes Endocrinology on 14 September 2025.
